Research Analysts Issue Forecasts for ACTU Q1 Earnings

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Actuate Therapeutics in a report released on Monday, August 18th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.25) for the quarter. HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Actuate Therapeutics' Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.99) EPS and FY2029 earnings at $0.21 EPS.

Separately, Craig Hallum began coverage on Actuate Therapeutics in a report on Tuesday, April 22nd. They set a "buy" rating and a $21.00 target price for the company.

Actuate Therapeutics Stock Up 1.6%

ACTU stock opened at $8.25 on Tuesday. Actuate Therapeutics has a twelve month low of $5.47 and a twelve month high of $11.99. The stock has a 50-day simple moving average of $7.11 and a two-hundred day simple moving average of $7.96.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

Insider Activity

In other Actuate Therapeutics news, Director Leslie W. Kreis purchased 71,428 shares of the company's stock in a transaction dated Friday, June 27th. The stock was purchased at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the transaction, the director owned 196,428 shares in the company, valued at $1,374,996. The trade was a 57.14% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Equity Cof Lp Bios purchased 71,428 shares of the company's stock in a transaction dated Friday, June 27th. The shares were acquired at an average price of $7.00 per share, with a total value of $499,996.00. Following the transaction, the director owned 196,428 shares in the company, valued at approximately $1,374,996. The trade was a 57.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 214,284 shares of company stock worth $1,499,988. 69.34% of the stock is currently owned by insiders.

Institutional Trading of Actuate Therapeutics

A number of hedge funds have recently bought and sold shares of ACTU. BIOS Capital Management LP bought a new stake in Actuate Therapeutics in the 4th quarter worth approximately $78,753,000. Voss Capital LP lifted its position in Actuate Therapeutics by 101.0% in the 2nd quarter. Voss Capital LP now owns 286,140 shares of the company's stock worth $1,748,000 after buying an additional 143,759 shares during the last quarter. Geode Capital Management LLC lifted its position in Actuate Therapeutics by 252.5% in the 2nd quarter. Geode Capital Management LLC now owns 118,050 shares of the company's stock worth $721,000 after buying an additional 84,561 shares during the last quarter. Gleason Group Inc. bought a new stake in Actuate Therapeutics in the 2nd quarter worth approximately $116,000. Finally, New York State Common Retirement Fund bought a new stake in Actuate Therapeutics in the 2nd quarter worth approximately $105,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.